RDY
Dr. Reddy's Laboratories Limited
NYSEUSDEQUITY
Healthcare
DELAYED
Neutral
-16/100
Last price
12.49
▲ 0.17 (1.38%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
12.32
Day high
12.56
Day low
12.32
Volume
4.00M
Market cap
$10.40B
P/E (TTM)
28.39
52W range
11.36 – 15.67
Trailing performance
Returnvs SPY
1W
-2.80%
-4.8%
1M
+4.34%
+3.2%
3M
-11.54%
-16.1%
6M
-3.55%
-21.7%
YTD
-11.04%
-25.3%
1Y
-11.79%
-28.2%
3Y
-6.61%
-88.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RDY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$10.40B
Enterprise value$56.13B
Revenue (TTM)$331.19B
Gross profit$166.18B
EBITDA$54.67B
Net income$33.11B
EPS (TTM)$0.44
Free cash flow$-3.91B
Total cash$81.43B
Total debt$71.95B
Book value / share$0.80
Shares outstanding832.99M
Float3.59B
Short % of float4.22%
Dividend yield0.67%
Beta (5Y)0.25
Valuation & profitability ratios
Trailing P/E28.39
Forward P/E19.38
PEG ratio1.65
Price / sales—
Price / book15.65
EV / revenue0.17
EV / EBITDA1.03
Gross margin50.18%
Operating margin4.25%
Profit margin10.00%
Return on equity8.84%
Return on assets4.01%
Debt / equity18.61
Current ratio1.90
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $335.93B | $325.54B | $279.16B | $245.88B | +3.2% |
| Operating revenue | $335.93B | $325.54B | $279.16B | $245.88B | +3.2% |
| Cost of revenue | $158.67B | $135.11B | $115.56B | $106.54B | +17.4% |
| Gross profit | $177.26B | $190.43B | $163.61B | $139.34B | -6.9% |
| Research & development | $24.06B | $27.38B | $22.87B | $19.38B | -12.1% |
| Selling, general & admin | $106.76B | $93.87B | $77.20B | $68.03B | +13.7% |
| Total operating expense | $127.14B | $118.41B | $98.30B | $80.29B | +7.4% |
| Operating income | $50.12B | $72.01B | $65.31B | $59.05B | -30.4% |
| Net interest income | -$12.00M | -$152.00M | $567.00M | -$248.00M | +92.1% |
| Pre-tax income | $54.82B | $76.78B | $71.87B | $60.37B | -28.6% |
| Tax provision | $12.35B | $19.54B | $16.19B | $15.30B | -36.8% |
| Net income | $42.85B | $56.54B | $55.68B | $45.07B | -24.2% |
| Net income to common | $42.85B | $56.54B | $55.68B | $45.07B | -24.2% |
| Basic EPS | 51.48 | 67.88 | 67.04 | 54.28 | -24.2% |
| Diluted EPS | 51.42 | 67.78 | 66.92 | 54.17 | -24.1% |
| EBIT | $58.55B | $79.61B | $73.58B | $61.80B | -26.5% |
| EBITDA | $79.16B | $96.67B | $88.42B | $74.43B | -18.1% |
| Basic shares | 832.44M | 832.95M | 831.98M | 830.17M | -0.1% |
| Diluted shares | 833.33M | 834.18M | 833.54M | 831.94M | -0.1% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.37B | $14.65B | $7.11B | $5.78B | — | +4.9% |
| Cash & short-term investments | $87.81B | $57.91B | $81.47B | $61.80B | — | +51.6% |
| Accounts receivable | $101.22B | $90.42B | $80.30B | $72.48B | — | +11.9% |
| Inventory | $76.53B | $71.08B | $63.55B | $48.67B | — | +7.7% |
| Total current assets | $301.98B | $250.11B | $248.05B | $204.25B | — | +20.7% |
| Property, plant & equipment | $115.93B | $97.76B | $76.89B | $66.46B | — | +18.6% |
| Goodwill & intangibles | $117.95B | $108.61B | $41.20B | $35.09B | — | +8.6% |
| Total assets | $579.35B | $492.99B | $387.52B | $321.85B | — | +17.5% |
| Total current liabilities | $167.57B | $130.39B | $96.04B | $85.84B | — | +28.5% |
| Current debt | $62.93B | $38.05B | $12.72B | $11.19B | — | +65.4% |
| Long-term debt | $12.20B | $3.80B | $3.80B | — | $3.80B | +221.1% |
| Total debt | $77.34B | $46.77B | $20.02B | $13.47B | — | +65.4% |
| Total liabilities | $198.89B | $155.82B | $106.97B | $90.86B | — | +27.6% |
| Retained earnings | $351.98B | $315.79B | $265.26B | $215.59B | — | +11.5% |
| Shareholder equity | $377.06B | $333.39B | $280.55B | $230.99B | — | +13.1% |
| Working capital | $134.41B | $119.72B | $152.01B | $118.41B | — | +12.3% |
| Net tangible assets | $259.11B | $224.78B | $239.35B | $195.90B | — | +15.3% |
| Shares issued | 834.66M | 834.46M | 834.09M | 832.64M | — | +0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $42.47B | $57.24B | $55.68B | $45.07B | -25.8% |
| Depreciation & amortisation | $20.61B | $17.06B | $14.84B | $12.64B | +20.8% |
| Stock-based compensation | $326.00M | $424.00M | $407.00M | $397.00M | -23.1% |
| Change in working capital | -$11.64B | -$29.99B | -$20.18B | -$7.86B | +61.2% |
| Operating cash flow | $56.76B | $46.43B | $45.43B | $58.88B | +22.2% |
| Capital expenditure | -$38.42B | -$34.40B | -$27.43B | -$18.87B | -11.7% |
| Investing cash flow | -$65.51B | -$58.08B | -$40.28B | -$41.37B | -12.8% |
| Share buybacks | $0 | -$1.39B | $0 | $0 | +100.0% |
| Dividends paid | -$6.66B | -$6.66B | -$6.65B | -$4.98B | +0.0% |
| Financing cash flow | $8.29B | $18.91B | -$3.76B | -$26.86B | -56.2% |
| Free cash flow | $18.33B | $12.03B | $18.00B | $40.01B | +52.4% |
| End cash position | $15.37B | $14.59B | $7.11B | $5.78B | +5.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $80.70B | $75.16B | $87.27B | $88.05B | $85.45B | — | +7.4% |
| Operating revenue | $80.70B | $75.16B | $87.27B | $88.05B | $85.45B | — | +7.4% |
| Cost of revenue | $43.16B | — | — | — | — | — | — |
| Gross profit | $37.54B | $43.03B | $46.81B | $48.14B | $48.63B | — | -12.8% |
| Research & development | $5.77B | — | $6.15B | $6.20B | $6.24B | $7.26B | — |
| Selling, general & admin | $26.10B | $14.47B | $26.92B | $26.44B | $23.18B | — | +80.4% |
| Total operating expense | $34.51B | $42.21B | $32.48B | $30.27B | $31.79B | — | -18.2% |
| Operating income | $3.03B | $829.00M | $14.33B | $17.87B | $16.84B | — | +265.9% |
| Net interest income | -$256.00M | -$1.06B | -$148.00M | $5.00M | $298.00M | — | +75.8% |
| Pre-tax income | $5.53B | $2.00B | $15.43B | $18.35B | $19.05B | — | +176.7% |
| Tax provision | $1.18B | -$216.00M | $3.53B | $4.08B | $4.95B | — | +645.4% |
| Net income | $4.43B | $2.21B | $12.10B | $14.37B | $14.18B | — | +100.8% |
| Net income to common | $4.43B | $2.21B | $12.10B | $14.37B | $14.18B | — | +100.8% |
| Basic EPS | 5.32 | 2.65 | 14.53 | 17.26 | 17.04 | — | +100.8% |
| Diluted EPS | 5.32 | 2.65 | 14.52 | 17.25 | 17.02 | — | +100.8% |
| EBIT | $6.78B | $3.05B | $16.37B | $19.26B | $19.88B | — | +122.0% |
| EBITDA | $12.15B | $8.63B | $21.59B | $24.31B | $24.64B | — | +40.8% |
| Basic shares | 833.65M | 833.58M | 832.62M | 832.68M | 832.04M | — | +0.0% |
| Diluted shares | 833.65M | 833.58M | 833.20M | 833.16M | 833.02M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.20B | $15.37B | $18.66B | $9.91B | $9.00B | — | -27.1% |
| Cash & short-term investments | $81.43B | $87.81B | $82.59B | $69.81B | $66.69B | — | -7.3% |
| Accounts receivable | $100.56B | $101.22B | $103.21B | $97.74B | $95.14B | — | -0.7% |
| Inventory | $80.47B | $76.53B | $79.01B | $75.82B | $75.60B | — | +5.2% |
| Total current assets | $299.33B | $301.98B | $297.55B | $279.52B | $269.90B | — | -0.9% |
| Property, plant & equipment | $115.55B | $115.93B | $115.54B | $111.98B | $102.78B | — | -0.3% |
| Goodwill & intangibles | $116.46B | $117.95B | $114.73B | $113.24B | $107.57B | — | -1.3% |
| Total assets | $575.30B | $579.35B | $562.90B | $542.00B | $519.54B | — | -0.7% |
| Total current liabilities | $157.34B | $167.57B | $158.31B | $150.93B | $142.59B | — | -6.1% |
| Current debt | $57.69B | $62.93B | $54.09B | $44.95B | $42.18B | — | -8.3% |
| Long-term debt | — | $12.20B | — | — | — | $3.80B | — |
| Total debt | $71.95B | $77.34B | $67.73B | $58.54B | $48.64B | — | -7.0% |
| Total liabilities | $188.57B | $198.89B | $187.14B | $179.92B | $165.78B | — | -5.2% |
| Retained earnings | $356.42B | $351.98B | $349.78B | $337.68B | $329.97B | — | +1.3% |
| Shareholder equity | $383.43B | $377.06B | $372.37B | $358.49B | $350.06B | — | +1.7% |
| Working capital | $141.99B | $134.41B | $139.24B | $128.59B | $127.31B | — | +5.6% |
| Net tangible assets | $266.96B | $259.11B | $257.64B | $245.25B | $242.49B | — | +3.0% |
| Shares issued | 834.95M | 834.66M | 834.63M | 834.61M | 834.58M | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $4.35B | $2.21B | $11.90B | $14.27B | $14.10B | +97.2% |
| Depreciation & amortisation | $5.37B | $5.58B | $5.21B | $5.05B | $4.76B | -3.7% |
| Stock-based compensation | $97.00M | $94.00M | $20.00M | $100.00M | $112.00M | +3.2% |
| Change in working capital | -$12.00B | $7.24B | -$8.13B | -$2.56B | -$8.19B | -265.8% |
| Operating cash flow | -$927.00M | $15.64B | $10.91B | $15.57B | $14.63B | -105.9% |
| Capital expenditure | -$3.70B | -$10.82B | -$7.32B | -$10.13B | -$10.15B | +65.8% |
| Investing cash flow | $3.84B | -$26.49B | -$10.29B | -$9.54B | -$19.19B | +114.5% |
| Dividends paid | $0 | $0 | $0 | -$6.66B | $0 | — |
| Financing cash flow | -$7.12B | $7.04B | $7.78B | -$5.32B | -$1.20B | -201.1% |
| Free cash flow | -$4.63B | $4.82B | $3.59B | $5.44B | $4.48B | -196.0% |
| End cash position | $11.20B | $15.37B | $18.66B | $9.91B | $9.00B | -27.1% |
Options analytics
Put / call volume
0.04
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
7.50
-40.0% from spot
ATM implied vol
0.4%
Nearest strike to spot
Skew (10% OTM)
-0.4%
Calls bid over puts
Call volume
53
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
7.50
0 contracts
Heaviest put OI
12.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $85.06B | -3.4% |
| Next quarter | — | — | $89.85B | +3.0% |
| Current year | 43.85 | 1 | $351.99B | +4.8% |
| Next year | 62.08 | 1 | $392.93B | +11.6% |
Analyst targets & ownership
Mean target$13.23
High target$15.23
Low target$11.24
Implied upside5.91%
Analyst count5
ConsensusNONE
Strong buy / Buy0 / 2
Hold2
Sell / Strong sell1 / 0
Held by insiders0.00%
Held by institutions16.00%
Institutions holding328
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
12.42
+0.54% from price
SMA 20
12.21
+2.29% from price
SMA 50
12.16
+2.74% from price
SMA 100
12.80
-2.40% from price
SMA 200
13.27
-5.91% from price
EMA 12
12.36
+1.04% from price
EMA 26
12.28
+1.67% from price
EMA 50
12.36
+1.08% from price
RSI (14)
55.1
Neutral
MACD (12,26,9)
0.08
Hist 0.02
ATR (14)
0.30
2.42% of price
Realised vol 30D
24.5%
Annualised
Bollinger upper
12.88
20, 2σ
Bollinger lower
11.54
20, 2σ
50 / 200 cross
Death
12.16 vs 13.27
Trend bias
Below 200
-5.91%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.25
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
24.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.0%
Peak to trough
Max drawdown 5Y
-32.4%
Peak to trough
ATR 14
0.30
2.42% of price
Beta (reported)
0.25
5Y monthly, from filing
Short interest
Shares short
28.96M
Prior 22.51M
Change vs prior
+28.6%
Shorts adding
% of float
4.22%
Normal
% of shares out
3.48%
Against total outstanding
Days to cover
10.9
Crowded exit
Float
3.59B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | Citigroup | UPGRADE | Sell | Buy |
| Jun 5, 25 | HSBC | UPGRADE | Hold | Buy |
| Nov 6, 24 | Barclays | MAINTAINED | Overweight | Overweight |
| Jul 30, 24 | Barclays | MAINTAINED | Overweight | Overweight |
| May 8, 24 | Barclays | MAINTAINED | Overweight | Overweight |
| Jan 29, 24 | Barclays | MAINTAINED | Overweight | Overweight |
| Jun 1, 23 | Barclays | MAINTAINED | Overweight | Overweight |
| Oct 31, 22 | Barclays | MAINTAINED | — | Overweight |
| Oct 25, 22 | Barclays | MAINTAINED | — | Overweight |
| Sep 12, 22 | Barclays | MAINTAINED | — | Overweight |
| Jul 25, 22 | Barclays | MAINTAINED | — | Overweight |
| May 24, 22 | Barclays | MAINTAINED | — | Overweight |
Dividends & splits
Forward rate$0.08 / yr
Forward yield0.67%
5-year avg yield0.65%
Payout ratio19.65%
Ex-dividend dateJul 9, 2026
Next pay dateAug 5, 2026
Last split5:1
Split dateNov 5, 2024
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-10-05
Corporate Changes & Voting Matters
6-K · 2026-09-22
Corporate Changes & Voting Matters
6-K · 2026-09-21
Corporate Changes & Voting Matters
6-K · 2026-09-18
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-09-10
Corporate Changes & Voting Matters
6-K · 2026-08-26
Corporate Changes & Voting Matters
6-K · 2026-08-17
Headlines
NBIX vs. TEVA: Which Drugmaker Is the Better Investment?
Zacks · 43d ago
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
Business Wire · 64d ago
Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...
GuruFocus.com · 71d ago
Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
Zacks · 76d ago
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
MarketBeat · 77d ago
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
MarketBeat · 86d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.